NCT00250640 - Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2012

Study Completion Date

July 31, 2012

Conditions

Hypertension, Pulmonary

Interventions

DRUG

Iloprost (Ventavis, BAYQ6256)

The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet

Trial Locations (43)

12200

Berlin

13353

Berlin

14004

Córdoba

20246

Hamburg

27100

Pavia

28041

Madrid

33604

Pessac

35392

Giessen

40138

Bologna

41069

Mönchengladbach

42283

Wuppertal

45147

Essen

50924

Cologne

51092

Reims

53105

Bonn

54500

Vandœuvre-lès-Nancy

56100

Pisa

59037

Lille

66421

Homburg/Saar

67091

Strasbourg

69120

Heidelberg

69126

Heidelberg

69394

Lyon

74245

Löwenstein

78166

Donaueschingen

80336

München

81377

München

91054

Erlangen

92141

Clamart

93053

Regensburg

99089

Erfurt

F-29609

Brest

01307

Dresden

04103

Leipzig

00161

Roma

3000-075

Coimbra

1150-291

Lisbon

08036

Barcelona

08035

Barcelona

G11 6NT

Glasgow

NW3 2PF

London

NE7 7DN

Newcastle upon Tyne

S10 2JF

Sheffield